| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:57 UTC |
|---|
| HMDB ID | HMDB0015331 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Bromocriptine |
|---|
| Description | Bromocriptine, also known as parlodel, belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids. Bromocriptine is a drug which is used for the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early parksinsonian syndrome or as an adjunct with levodopa in advanced cases with motor complications. bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. Bromocriptine is a very strong basic compound (based on its pKa). Bromocriptine use has been anecdotally associated with causing or worsening psychotic symptoms (its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine receptors). Bromocriptine is a potentially toxic compound. Bromocriptine is a semisynthetic derivative of a natural ergot alkaloid, ergocryptine (a derivative of lysergic acid), which is synthesized by bromination of ergocryptine using N-bromosuccinimide. Since the late 1980s it has been used, off-label, to reduce the symptoms of cocaine withdrawal but the evidence for this use is poor. It is a bile salt export pump inhibitor. As of July 2017, bromocriptine was marketed under many brand names worldwide, including Abergin, Barlolin, Brameston, Brocriptin, Brom, Broma-Del, Bromergocryptine, Bromergon, Bromicon, Bromocorn, Bromocriptin, Bromocriptina, Bromocriptine, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, Bromocriptini mesilas, Bromocriptinmesilat, Bromodel, Bromokriptin, Bromolac, Bromotine, Bromtine, Brotin, Butin, Corpadel, Cripsa, Criptine, Criten, Cycloset, Degala, Demil, Deparo, Deprolac, Diacriptin, Dopagon, Erenant, Grifocriptina, Gynodel, kirim, Kriptonal, Lactodel, Medocriptine, Melen, Padoparine, Palolactin, Parlodel, Pravidel, Proctinal, Ronalin, Semi-Brom, Serocriptin, Serocryptin, Suplac, Syntocriptine, Umprel, Unew, Updopa, Upnol B, and Volbro. Bromocriptine is a potent agonist at dopamine D2 receptors and various serotonin receptors. Bromocriptine (originally marketed as Parlodel, subsequently under many names) is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease (PD), hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. Most frequent side effects are nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre. |
|---|
| Structure | [H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman | ChEBI | | (5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione | ChEBI | | (5'alpha)-2-Bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman | ChEBI | | 2-Bromo-alpha-ergocryptine | ChEBI | | 2-Bromo-alpha-ergokryptin | ChEBI | | 2-Bromo-alpha-ergokryptine | ChEBI | | Bromocriptinum | ChEBI | | Bromocryptine | ChEBI | | Bromoergocriptine | ChEBI | | (5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman | Generator | | (5'Α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman | Generator | | (5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione | Generator | | (5'Α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione | Generator | | (5'a)-2-Bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman | Generator | | (5'Α)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman | Generator | | 2-Bromo-a-ergocryptine | Generator | | 2-Bromo-α-ergocryptine | Generator | | 2-Bromo-a-ergokryptin | Generator | | 2-Bromo-α-ergokryptin | Generator | | 2-Bromo-a-ergokryptine | Generator | | 2-Bromo-α-ergokryptine | Generator | | Bromergocryptine | HMDB | | Bromocriptin | HMDB | | Bromocriptine methanesulfonate | HMDB | | Bromoergocryptine | HMDB | | 2 Bromo alpha ergocryptine | HMDB | | 2 Bromoergocryptine mesylate | HMDB | | 2 Bromoergokryptine | HMDB | | 2-Bromoergocryptine mesylate | HMDB | | Mesylate, bromocriptine | HMDB | | Methanesulfonate, 2-bromoergocryptine | HMDB | | Parlodel | HMDB | | 2 Bromoergocryptine | HMDB | | 2 Bromoergocryptine methanesulfonate | HMDB | | 2-Bromoergocryptine | HMDB | | 2-Bromoergocryptine methanesulfonate | HMDB | | 2-Bromoergokryptine | HMDB | | Mesylate, 2-bromoergocryptine | HMDB | | 2 Bromo alpha ergokryptine | HMDB | | Bromocriptine mesylate | HMDB | | Bromocryptin | HMDB |
|
|---|
| Chemical Formula | C32H40BrN5O5 |
|---|
| Average Molecular Weight | 654.595 |
|---|
| Monoisotopic Molecular Weight | 653.221282062 |
|---|
| IUPAC Name | (4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide |
|---|
| Traditional Name | bromocriptine |
|---|
| CAS Registry Number | 25614-03-3 |
|---|
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C |
|---|
| InChI Identifier | InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 |
|---|
| InChI Key | OZVBMTJYIDMWIL-AYFBDAFISA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Ergoline and derivatives |
|---|
| Sub Class | Lysergic acids and derivatives |
|---|
| Direct Parent | Lysergamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Lysergic acid amide
- Indoloquinoline
- Benzoquinoline
- N-acyl-alpha amino acid or derivatives
- Pyrroloquinoline
- Alpha-amino acid or derivatives
- Quinoline
- 3-alkylindole
- Indole
- Indole or derivatives
- Isoindole or derivatives
- Aralkylamine
- N-alkylpiperazine
- Aryl bromide
- Aryl halide
- 1,4-diazinane
- Oxazolidinone
- Piperazine
- Substituted pyrrole
- Benzenoid
- Heteroaromatic compound
- Pyrrolidine
- Pyrrole
- Tertiary carboxylic acid amide
- Oxazolidine
- Carboxamide group
- Lactam
- Tertiary amine
- Tertiary aliphatic amine
- Orthocarboxylic acid derivative
- Amino acid or derivatives
- Azacycle
- Oxacycle
- Carboxylic acid derivative
- Alkanolamine
- Carboximidic acid derivative
- Propargyl-type 1,3-dipolar organic compound
- Carboximidic acid
- Organic 1,3-dipolar compound
- Organoheterocyclic compound
- Organic nitrogen compound
- Amine
- Organopnictogen compound
- Organic oxide
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Organohalogen compound
- Organobromide
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.086 g/L | Not Available | | LogP | 3.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.62 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.6375 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.92 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 68.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2742.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 160.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 215.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 151.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 161.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 587.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 604.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 173.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1237.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 588.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1832.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 353.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 449.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 170.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 197.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Bromocriptine,1TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4653.5 | Semi standard non polar | 33892256 | | Bromocriptine,1TMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4505.9 | Semi standard non polar | 33892256 | | Bromocriptine,1TMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4659.1 | Semi standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4511.3 | Semi standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4733.3 | Standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 6106.8 | Standard polar | 33892256 | | Bromocriptine,2TMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4610.7 | Semi standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4699.1 | Standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 6116.4 | Standard polar | 33892256 | | Bromocriptine,2TMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4536.0 | Semi standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4747.1 | Standard non polar | 33892256 | | Bromocriptine,2TMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 6059.1 | Standard polar | 33892256 | | Bromocriptine,3TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4543.0 | Semi standard non polar | 33892256 | | Bromocriptine,3TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 4756.7 | Standard non polar | 33892256 | | Bromocriptine,3TMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C)C(=O)N12 | 5770.4 | Standard polar | 33892256 | | Bromocriptine,1TBDMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4845.6 | Semi standard non polar | 33892256 | | Bromocriptine,1TBDMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 4721.5 | Semi standard non polar | 33892256 | | Bromocriptine,1TBDMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4814.6 | Semi standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 4896.0 | Semi standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 5168.4 | Standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #1 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)[NH]6)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 6104.9 | Standard polar | 33892256 | | Bromocriptine,2TBDMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 4966.5 | Semi standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 5142.2 | Standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #2 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O[Si](C)(C)C(C)(C)C)O[C@](NC(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)(C(C)C)C(=O)N12 | 6115.0 | Standard polar | 33892256 | | Bromocriptine,2TBDMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 4890.8 | Semi standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 5183.5 | Standard non polar | 33892256 | | Bromocriptine,2TBDMS,isomer #3 | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(C)C)(N(C(=O)[C@@H]3C=C4C5=CC=CC6=C5C(=C(Br)N6[Si](C)(C)C(C)(C)C)C[C@H]4N(C)C3)[Si](C)(C)C(C)(C)C)C(=O)N12 | 6059.9 | Standard polar | 33892256 |
|
|---|